Oculis Holding AG (NASDAQ:OCSAW – Get Free Report) was the target of a large increase in short interest in October. As of October 15th, there was short interest totaling 17,410 shares, an increase of 111.0% from the September 30th total of 8,251 shares. Based on an average daily volume of 6,891 shares, the short-interest ratio is presently 2.5 days.
Oculis Price Performance
Shares of NASDAQ:OCSAW remained flat at $2.45 during midday trading on Friday. Oculis has a fifty-two week low of $2.01 and a fifty-two week high of $22.64. The company has a 50-day moving average of $3.30 and a two-hundred day moving average of $9.75.
Oculis Company Profile
Oculis is a clinical-stage biopharmaceutical company focused on developing innovative ophthalmic treatments. The company uses its proprietary OPTIREACH technology platform to develop eye-drop formulations designed to deliver medicines to tissues at the back of the eye, potentially addressing conditions that traditionally require injections or other invasive procedures.
Oculis’ development portfolio has included treatments for retinal diseases, glaucoma and ocular surface disorders. Its investigational products have targeted conditions such as diabetic macular edema, dry eye disease and neurodegenerative eye diseases.
See Also
- Five stocks we like better than Oculis
- Starbucks Says Its Turnaround Is Done—The Numbers Make a Strong Case (With 1 Catch)
- 3 Robotics ETFs, 3 Different Ways to Bet on Humanoid Robots
- Can Microsoft Turn a Leaner Workforce and Record AI Spending Into Bigger Profits?
- Why JFrog Could Be the Software Infrastructure Company to Beat in the AI Boom
Receive News & Ratings for Oculis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oculis and related companies with MarketBeat.com's FREE daily email newsletter.
